News & Updates

Show Multimedia Only
Achieving ultra-low PSA levels with ADT plus ARPI improves mHSPC outcomes in a patient with comorbidities
Achieving ultra-low PSA levels with ADT plus ARPI improves mHSPC outcomes in a patient with comorbidities
11 Dec 2025 byDr. Emerson Kwan-Ho Leung, Specialist in Clinical Oncology, Hong Kong

A 70-year-old male was diagnosed with prostate cancer (PC) after presenting with increased urinary frequency and an elevated prostate-specific antigen (PSA) level of 71 ng/mL in October 2022. (Figure) MRI revealed a 3 cm left prostatic lesion without pelvic lymph node involvement or bone metastases, with possible extra­prostatic extension and seminal vesicle invasion. Transperineal ultrasound-guided prostate biopsy confirmed prostatic ade­nocarcinoma in 8 out of 12 cores, with a Gleason score of 4 + 3. 

Achieving ultra-low PSA levels with ADT plus ARPI improves mHSPC outcomes in a patient with comorbidities
11 Dec 2025